Deciphering the Complexity of MEK Mutations in the Clinic

Significant advances in tumor sequencing have led to an explosion in our knowledge of the genetic complexity of cancer. For many cancers, the selection of a targetable alteration is not readily apparent, especially when confronted with mutational variants of unknown significance. The complex clinica...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2020-10, Vol.80 (19), p.4042-4043
Main Authors: Whitehead, Christopher E, Sebolt-Leopold, Judith S
Format: Article
Language:English
Subjects:
Benchmarking
Computer Simulation
Humans
Mitogen-Activated Protein Kinase Kinases
Mutation
Neoplasms - genetics
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Significant advances in tumor sequencing have led to an explosion in our knowledge of the genetic complexity of cancer. For many cancers, the selection of a targetable alteration is not readily apparent, especially when confronted with mutational variants of unknown significance. The complex clinical landscape of mutations illustrates the need for improved methods to identify those patients, independent of tumor histology, who would benefit from treatment with a MAP kinase pathway inhibitor. In this issue of , Hanrahan and colleagues adopt an platform to attempt to distinguish benign mutations from those that are functional and, therefore, most likely to be therapeutically actionable. .
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-20-2611